2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183291
    Antibacterial agent 343
    Antibacterial agent 343 (Compound 47) is an Antibacterial agent. Antibacterial agent 343 binds to the allosteric site of PBP2a to open its active site. Antibacterial agent 343 disrupts bacterial cell membranes, leading to protein leakage. Antibacterial agent 343 interacts with DNA and inhibits replication and transcription. Antibacterial agent 343 induces ROS accumulation. Antibacterial agent 343 exhibits antibacterial activity against MRSA, Staphylococcus aureus, and Enterococcus faecalis. Antibacterial agent 343 can be used for the research of methicillin-resistant Staphylococcus aureus infections.
    Antibacterial agent 343
  • HY-183295
    Antifungal agent 160 3103869-13-9 98%
    Antifungal agent 160 is a cytochrome bc1 complex inhibitor with activity against Alternaria solani, Gibberella zeae, Colletotrichum gloeosporioides, and Fusarium oxysporum f. sp. melonis. Antifungal agent 160 impairs ATP synthesis, suppresses ATPase activity, induces ROS bursts, compromises plasma membrane integrity, and suppresses fungal growth. Antifungal agent 160 can be used for the research of fungal infection.
    Antifungal agent 160
  • HY-183305
    Antibiofilm-IN-1
    Antibiofilm-IN-1 (Compound 10) is a biofilm inhibitor and Antibacterial agent. Antibiofilm-IN-1 potently inhibits biofilm formation by Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa.
    Antibiofilm-IN-1
  • HY-183308
    Antifungal agent-161
    Antifungal agent-161 (Compound 7) is an Antifungal agent. Antifungal agent-161 potently inhibits Candida albicans ATCC 36082 (with a MIC of 1.32 μM) and Candida glabrata ATCC 2001 (with a MIC of 1.66 μM). Antifungal agent-161 reduces fungal loads in infected mice and eliminates Candida albicans and Candida glabrata infections. Antifungal agent-161 can be used for the research of candidiasis.
    Antifungal agent-161
  • HY-183313
    IAV-IN-5 3038861-11-6 98%
    IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection.
    IAV-IN-5
  • HY-183314
    ZIKV-IN-9
    ZIKV-IN-9 is a ZIKV inhibitor that blocks the early binding of viral particles to the cell surface. ZIKV-IN-9 inhibits ZIKV in various cell models. ZIKV-IN-9 is applicable to research related to Zika virus infection.
    ZIKV-IN-9
  • HY-183322
    Antiviral agent 83
    Antiviral agent 83 is a boronic acid-modified Neocryptolepine (HY-E70250) derivative and is an anti-HPV agent. Antiviral agent 83 bind to the viral capsid protein and/or envelope protein, inducing conformational changes that effectively obstruct the interaction between the virus and host cell receptors. Antiviral agent 83 exhibits inhibitory activity against multiple high-risk HPV strains. Antiviral agent 83 inhibits HPV infection in vitro and in vaginal tract in vivo.
    Antiviral agent 83
  • HY-183323
    MmpL3-IN-6
    MmpL3-IN-6 is a mycobacterial membrane protein large 3 (MmpL3) transporter inhibitor and is an antitubercular agent. MmpL3-IN-6 exerts bactericidal activity against replicating Mycobacterium tuberculosis.MmpL3-IN-6 retains activity against drug-resistant Mycobacterium tuberculosis.MmpL3-IN-6 can be used for the research of tuberculosis.
    MmpL3-IN-6
  • HY-183331
    YXX0237 860445-85-8 98%
    YXX0237 is an orally active anti-hypoxic agent. YXX0237 upregulates mRNA expression of FGF21 and GDF15 via activation of the ISR/ATF4 transcriptional axis. YXX0237 exhibits low cytotoxicity. YXX0237 enhances hypoxic survival in mice. YXX0237 can be used for the research of acute mountain sickness and hypoxia-related diseases.
    YXX0237
  • HY-183333
    CHNQD-02204 3094676-22-6
    CHNQD-02204 is a potent and selective antifungal agent with in vitro activity against Candida albicans, with a MIC of 0.025 μg/mL. CHNQD-02204 inhibits ergosterol biosynthesis, disrupts the membrane integrity and biofilm formation of Candida albicans, and suppresses the morphological transition of Candida albicans from yeast to hyphal form. CHNQD-02204 can be used in studies related to candidal infections.
    CHNQD-02204
  • HY-183340
    Antibacterial agent 341 3023862-30-5
    Antibacterial agent 341 is an anti-bacterial agent. Antibacterial agent 341 shows broad-spectrum Gram-positive antibacterial activity. Antibacterial agent 341 targets phosphatidylglycerol (PG) and cardiolipin (CL) in bacterial cell membranes, induces sustained depolarization of membranes, and disrupts the cell membrane integrity. Antibacterial agent 341 exhibits anti-infection activity against S. aureus-induced subcutaneous abscesses in mice.
    Antibacterial agent 341
  • HY-183361
    Antibiofilm agent-22 98%
    Antibiofilm agent-22 is an FpvA receptor-targeting antibacterial agent. Antibiofilm agent-22 chelates iron, disrupts las, pqs, and rhl pathways, reduces elastase, pyocyanin, and rhamnolipid production, and induces bacterial iron starvation. Antibiofilm agent-22 can be used for the research of Pseudomonas aeruginosa infection.
    Antibiofilm agent-22
  • HY-183362
    Antileishmanial agent-42 98%
    Antileishmanial agent-42 is an antileishmanial agent. Antileishmanial agent-42 has favorable interactions with key active site residues (e.g., Ser63, Asn66/295/299) of adenosine kinase. Antileishmanial agent-42 exerts activity against promastigote and amastigote forms of L. amazonensis, L. braziliensis, L. infantum, and L. donovani.
    Antileishmanial agent-42
  • HY-183542
    DprE1-IN-15 98%
    DprE1-IN-15 is a covalent Mycobacterium tuberculosis essential cell wall enzyme DprE1 inhibitor with an IC50 of 0.073 μM. DprE1-IN-15 forms an irreversible covalent adduct with its target enzyme. DprE1-IN-15 shows inhibitory effects against multiple Mycobacterium tuberculosis.
    DprE1-IN-15
  • HY-183552
    mCPX 1351572-56-9
    mCPX is a prodrug of the antifungal agent Ciclopirox olamine (CPX) (HY-B0450A). CPX exhibits bacteriostatic and iron-chelating activities, while mCPX enhances the iron stability of CPX. mCPX inherits the core mechanism pathway of CPX and can induce EBV lytic reactivation in EBV+ gastric cancer cells via the hypoxia pathway (HIF‑1α). mCPX is applicable to research related to EBV-positive gastric cancer.
    mCPX
  • HY-183606
    Mycobacterium tuberculosis-IN-9
    Mycobacterium tuberculosis-IN-9 is an orally active Mycobacterium tuberculosis BioA inhibitor with a Ki value of 0.2 nM. Mycobacterium tuberculosis-IN-9 targets the biotin biosynthesis pathway. Mycobacterium tuberculosis-IN-9 inhibits the growth of Mycobacterium tuberculosis in mouse models and is effective against both drug-sensitive and drug-resistant strains. Mycobacterium tuberculosis-IN-9 can be used for the research of tuberculosis.
    Mycobacterium tuberculosis-IN-9
  • HY-183611
    LPZ-51
    LPZ-51 is a Vibrio β-lactam resistance sensor kinase (VbrK) inhibitor with a Ki value of 1.09 μM. LPZ-51 inhibits blaA gene expression at the transcriptional level by blocking the kinase activity of VbrK, reduces β-lactamase synthesis, and does not affect bacterial growth. LPZ-51 acts synergistically with β-lactam antibiotics. LPZ-51 decreases bacterial load, alleviates intestinal inflammation, and improves survival rate in zebrafish infection models. LPZ-51 can be used in studies related to Vibrio parahaemolyticus infection.
    LPZ-51
  • HY-183670
    JAK2-IN-21 3038340-43-8
    JAK2-IN-21 is a Janus kinase 2 (JAK2) inhibitor with an IC50 of 12.25 nM. JAK2-IN-21 inhibits the JAK2/STAT3/STAT5 tumor-promoting signaling pathway and reduces JAK2 protein expression. JAK2-IN-21 exhibits selective cytotoxicity against HPV-positive cancer cells and induces cancer cell apoptosis. JAK2-IN-21 can be used in the research of HPV-positive cervical cancer.
    JAK2-IN-21
  • HY-183702
    BDM91531 2892824-73-4 98%
    BDM91531 is a AcrB inhibitor with an EC50 of 0.16 μM against E. coli. BDM91531 acts as an antibiotic potentiator to restore the sensitivity of wild-type Escherichia coli to multiple AcrB substrate antibiotics. BDM91531 exhibits antibacterial activity. BDM91531 can be used in the research of bacterial infections.
    BDM91531
  • HY-183737
    ATG5/TECAIR-IN-1 2841473-83-2 98%
    ATG5/TECAIR-IN-1 is a ATG5-TECAIR interaction inhibitor with an IC50 of 20.79 μM. ATG5/TECAIR-IN-1 inhibits autophagy. TG5/TECAIR-IN-1 is applicable to research on modulating protein-protein interactions to intervene in autophagy-related diseases, such as infectious diseases and cancers.
    ATG5/TECAIR-IN-1
Cat. No. Product Name / Synonyms Application Reactivity